Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.
Oct 08 2013
Versartis Closes $20 Million Series D Venture Financing
Sep 22 2013
Versartis Presents Latest Positive Results from its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference
Sep 13 2013
Versartis Receives Orphan Drug Status for its Novel Long-Acting Growth Hormone Treatment from European Commission